Material Agreements

Oklo Inc. terminated Equity Distribution Agreement with Goldman Sachs & Co. LLC, BofA Securities, Inc., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC, Barclays Capital Inc., TD Securities (USA) LLC, Guggenheim Securities, LLC, B. Riley Securities, Inc. and William Blair & Company, L.L.C. (effective 2026-05-13).

“On May 13, 2026, the Company delivered written notice of its intention to terminate the Equity Distribution Agreement, dated as of December 4, 2025 (the “Prior Sales Agreement”), by and among the Company and each of Goldman Sachs & Co. LLC, BofA Securities, Inc., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC, Barclays Capital Inc., TD Securities (USA) LLC, Guggenheim Securities, LLC, B. Riley Securities, Inc. and William Blair & Company, L.L.C.”

Oklo Inc. entered into Sales Agreement with Goldman Sachs & Co. LLC, BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Barclays Capital Inc., Cantor Fitzgerald & Co., Guggenheim Securities, LLC, Canaccord Genuity LLC and William Blair & Company, L.L.C. valued at aggregate gross sales proceeds of up to $1,000,000,000 (effective 2026-05-13).

“On May 13, 2026, Oklo Inc. (the “Company”) entered into an equity distribution agreement (the “Sales Agreement”) with Goldman Sachs & Co. LLC, BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Barclays Capital Inc., Cantor Fitzgerald & Co., Guggenheim Securities, LLC, Canaccord Genuity LLC and William Blair & Company, L.L.C. under which the Company may offer and sell, from time to time in its sole discretion, shares of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), with aggregate gross sales proceeds of up to $1,000,000,000”

ACUITY INC. (DE) entered into Credit Agreement with JPMorgan Chase Bank, N.A. valued at $800 million unsecured revolving credit facility maturing in May 2031 (effective 2026-05-08).

“On May 8, 2026, Acuity Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) among the Company, the subsidiary borrowers from time to time party thereto, the various lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as administrative agent.”

Nuvve Holding Corp. entered into Registration Rights Agreement with certain investors signatory thereto valued at Company agreed to file a registration statement covering the public resale of Exchange Shares, Pre-F (effective 2026-05-12).

“Also on May 12, 2026, the Company and certain investors signatory thereto entered into a registration rights agreement (the “Registration Rights Agreement) pursuant to which the Company agreed to file a registration statement with the Securities and Exchange Commission covering the public resale of (i) the Exchange Shares, (ii) the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants and (iii) the shares of Common Stock issuable pursuant to the conversion of the Series A Preferred Stock, including such shares of Common Stock issuable upon payment of dividends on the Series A Preferred Stock.”

Nuvve Holding Corp. amended 2025 Securities Purchase Agreement with Holders valued at Amendment and restatement of Section 4.12(a) to divide the subsequent financing participation right (effective 2026-05-12).

“Pursuant to the Exchange Agreement, the Company and Holders agreed to amend and restate Section 4.12(a) of the 2025 Securities Purchase Agreement to provide that the subsequent financing participation right of the Purchasers (as defined therein) would be divided pro rata among the Purchasers based upon their ownership percentage of the Existing Warrants.”

Nuvve Holding Corp. terminated Common Shares Purchase Agreement (ELOC Agreement) with certain investors signatory to the ELOC Agreement valued at Termination of the ELOC Agreement effective as of Closing; investors waived notice requirements (effective 2026-05-12).

“Pursuant to the Exchange Agreement, the Company provided notice that effective as of the Closing, the Company shall terminate that certain common shares purchase agreement, dated November 14, 2025, (the “ELOC Agreement”) between the Company and certain investors signatory thereto pursuant to Section 8.2 of the ELOC Agreement and such investors agreed to waive the notice requirements set forth in Section 8.2 and 10.4 of the ELOC Agreement.”

Nuvve Holding Corp. terminated 2024 Additional Investment Right and 2025 Additional Investment Right with Holders valued at Irrevocable waiver, relinquishment and termination of Additional Investment Rights; Holders also agr (effective 2026-05-12).

“Pursuant to the Exchange Agreement, the Company and the Holders, agreed that upon the Closing (as defined below), the Holders would irrevocably waive, relinquish and terminate the Holders’ certain additional investment right to purchase additional securities of the Company as provided under that certain securities purchase agreement dated as of November 14, 2025 (the “2025 Additional Investment Right”) and that certain additional investment right to purchase additional securities of the Company as provided under that certain securities purchase agreement dated as of October 31, 2024 (the “2024 Additional Investment Right” and together with the 2025 Additional Investment Right, the “Additional Investment Rights”) and providing that neither the Company nor the Holders shall have any further rights or obligations with respect to the Additional Investment Rights.”

Nuvve Holding Corp. amended Certificate of Designation Amendment for Series A Convertible Preferred Stock with holders of a majority of outstanding Series A Preferred Stock valued at Amendment to remove the Floor Price as a limitation on adjustments to the conversion price of Series (effective 2026-05-12).

“Pursuant to the Exchange Agreement, the Company and the Holders, holding a majority of the outstanding shares of the Company’s Series A Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), agreed to amend the terms of the Series A Preferred Stock in the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “Certificate of Designation Amendment”) to remove the Floor Price (as defined therein) as a limitation on adjustments to the conversion price of the Series A Preferred Stock, including adjustments arising from certain price-based anti-dilution adjustments.”

Nuvve Holding Corp. entered into Securities Exchange and Omnibus Amendment Agreement with certain holders of warrants valued at Exchange of Existing Warrants for 13,107,127 shares of Common Stock or Pre-Funded Warrants (effective 2026-05-12).

“On May 12, 2026, Nuvve Holding Corp. (the “Company”) entered into a securities exchange and omnibus amendment agreement (the “Exchange Agreement”) with certain holders (the “Holders”) of warrants exercisable for an aggregate of up to 23,831,137 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), consisting of (i) certain common stock purchase warrants of the Company originally issued on October 31, 2024 and having a current exercise price of $0.4734 (such warrants, the “2024 Private Placement Warrants”); (ii) certain common stock purchase warrants of the Company issued upon the exercise of certain 2024 Additional Investment Rights (as defined below) and having a current exercise price of 0.4734 (such warrants, the “2024 AIR Warrants”); (iii) certain common stock purchase warrants of the Company originally issued on December 30, 2025 and having a current exercise price of 0.4734 (such warrants, the “2025 Private Placement Warrants”); (iv) certain comm”

Xos, Inc. amended Third Amended and Restated Convertible Promissory Note with Aljomaih Automotive Co. valued at $20 million (effective 2026-05-08).

“On May 8, 2026 , the Company and Aljomaih Automotive Co. ("Aljomaih") entered into a Third Amended and Restated Convertible Promissory Note (the "Third A&R Note") .”

iSpecimen Inc. entered into Securities Purchase Agreement with certain accredited investors valued at aggregate gross proceeds of approximately $2.5 million (effective 2026-05-08).

“On May 8, 2026, iSpecimen Inc., a Delaware corporation (Nasdaq: ISPC) (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell 488,281 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock” or “Shares”), at a purchase price of $5.12 per Share.”

LINCOLN EDUCATIONAL SERVICES CORP entered into Purchase and Sale Agreement with Melrose Omni, LLC valued at $18,800,000.00 (effective 2026-05-12).

“On May 12, 2026, Lincoln Technical Institute, Inc. (“Lincoln Technical Institute”), a wholly-owned subsidiary of Lincoln Educational Services Corporation, entered into a purchase and sale agreement (the “Purchase and Sale Agreement”) with Melrose Omni, LLC, an Illinois limited liability company (the “Seller”), pursuant to which the Seller has agreed to sell to Lincoln Technical Institute the real property owned by the Seller located at 8315-8317 W. North Avenue, Melrose Park, IL 60160, including the building and improvements and other personal property located thereon (the “Property”), for a purchase price of $18,800,000.00 as adjusted in accordance with the terms of the Purchase and Sale Agreement.”

CEL SCI CORP entered into Placement Agency Agreement with ThinkEquity LLC valued at $7,200,000 gross proceeds from offering of 6,000,000 shares at $1.20 per share (effective 2026-05-11).

“On May 11, 2026, CEL-SCI Corporation, a Colorado corporation (the “Company”), entered into a Placement Agency Agreement with ThinkEquity LLC (the “Placement Agent”) relating to the sale and issuance of 6,000,000 shares of the Company’s common stock, at an offering price of $1.20 per share (the “Shares”).”

Sun Country Airlines Holdings, Inc. terminated Credit and Guaranty Agreement with MUFG Bank, Ltd., Sumitomo Mitsui Banking Corporation, UMB Bank, N.A. (effective 2026-05-13).

“On May 13, 2026, in connection with the consummation of the Mergers (as defined below), Sun Country, Inc., a Minnesota corporation and a wholly owned subsidiary of Sun Country Airlines Holdings, Inc., a Delaware corporation (“ Sun Country ”) terminated the Credit and Guaranty Agreement, dated as of March 24, 2025, by and among Sun Country, Inc., Sun Country, as Guarantor, MUFG Bank, Ltd., as a Lender, Sumitomo Mitsui Banking Corporation, as a Lender and UMB Bank, N.A., as administrative agent and security trustee, as such agreement may be amended, restated, supplemented, refinanced, replaced or otherwise modified from time to time, and all commitments and obligations under such agreement, other than certain continuing indemnity obligations, were satisfied and discharged in full.”

NexPoint Real Estate Finance, Inc. entered into Credit Agreement with VineBrook Homes Operating Partnership, L.P. valued at $20.0 million (effective 2026-05-07).

“entered into a secured $20.0 million revolving credit agreement (the “Credit Agreement”) with VineBrook Homes Operating Partnership, L.P., as borrower”

Outlook Therapeutics, Inc. terminated Prior At-The-Market Sales Agreement with BTIG, LLC valued at at-the-market offering program under which the Company could offer and sell shares of its Common Sto (effective 2026-05-12).

“In connection with entering into the Sales Agreement, the Company terminated, effective May 12, 2026, its at-the-market sales agreement, dated as of May 16, 2023 (as amended, the “Prior Sales Agreement”) with BTIG, LLC with respect to an at-the-market offering program under which the Company could offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to $100,000,000 (the “Prior ATM Program”).”

Outlook Therapeutics, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at aggregate offering price of up to $100,000,000 (effective 2026-05-13).

“On May 13, 2026, Outlook Therapeutics, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright”), pursuant to which the Company may issue and sell shares of its common stock, $0.01 par value per share (“Common Stock”), from time to time through H.C. Wainwright as sales agent and/or principal having an aggregate offering price of up to $100,000,000 (the “Shares”).”

Prestige Consumer Healthcare Inc. entered into Sale and Purchase Deed with Tailor Investments Pty Limited and Standive Pty Limited valued at approximately $150 million in cash (effective 2026-05-10).

“On May 10, 2026, PBH Australia Holding Company Pty Limited ("Purchaser"), an Australian company and a wholly owned indirect subsidiary of Prestige Consumer Healthcare Inc. (the "Company"), and Care Pharmaceuticals Pty Limited ("Care"), an Australian company and a wholly owned indirect subsidiary of the Company, entered into a definitive agreement (the "Sale and Purchase Deed") with Tailor Investments Pty Limited and Standive Pty Limited, both Australian companies (the "Sellers"), Steven David Sher, Delon Badler and Clive Howard Sher.”

Armata Pharmaceuticals, Inc. entered into May 2026 Credit Agreement with Innoviva Strategic Opportunities LLC (Innoviva) valued at $25 million (effective 2026-05-12).

“on May 12, 2026, it had entered into, as borrower, a credit and security agreement (the “May 2026 Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company. The May 2026 Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million”

MOHAWK INDUSTRIES INC entered into New Credit Agreement with JPMorgan Chase Bank, N.A. and J.P. Morgan SE, as U.S. administrative agent and non-U.S. administrative agent (together, the “Administrative Agent”), and certain lenders party thereto valued at $1,500,000,000 (effective 2026-05-12).

“(the “Company”) entered into a New Credit Agreement (as defined hereafter), and, substantially contemporaneously therewith, the Company terminated all outstanding commitments and repaid all outstanding obligations under that certain”

MOHAWK INDUSTRIES INC terminated Existing Credit Facility with Wells Fargo Bank, National Association, as administrative agent, swing line lender, and an L/C issuer, and the other lenders party thereto (effective 2026-05-12).

“the Company terminated all outstanding commitments and repaid all outstanding obligations under that certain Second Amended and Restated Credit Agreement, dated as of October 18, 2019”

Linkhome Holdings Inc. amended Amendment No. 1 to the Stock Purchase Agreement with Constant Investments, Inc. (doing business as Mortgage One Group), Jun Choi, Richard Tak (effective 2026-05-12).

“On May 12, 2026, Linkhome, the Target, and the Sellers entered into Amendment No. 1 to the Stock Purchase Agreement (the “Amendment”).”

Linkhome Holdings Inc. entered into Stock Purchase Agreement with Constant Investments, Inc. (doing business as Mortgage One Group), Jun Choi, Richard Tak valued at 300,000 shares of common stock and earnout of up to $750,000 in cash (effective 2026-05-08).

“On May 8, 2026, Linkhome Holdings Inc. (the “Company” or “Linkhome”) entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Constant Investments, Inc., a Texas corporation doing business as Mortgage One Group (the “Target”), and Jun Choi and Richard Tak, the sole shareholders of the Target (the “Sellers”).”

XCF Global, Inc. entered into Encore Agreement with Encore DEC, LLC valued at approximately $16.7 million (effective 2026-05-06).

“On May 6, 2026, the Company, New Rise Renewables Reno, LLC (“ New Rise Reno ”), a subsidiary of the Company, and Encore DEC, LLC (“ Encore ”) entered into a payable acknowledgement and settlement agreement (the “ Encore Agreement ”), pursuant to which approximately $16.7 million of outstanding accounts payable due to Encore DEC will be settled through the issuance of 37,033,386 shares of the Company’s Class A Common Stock”

APPLIED OPTOELECTRONICS, INC. entered into Leases with Hightower Phase I Owner, LLC (effective 2026-05-08).

“On May 8, 2026, Applied Optoelectronics, Inc. (the "Company") entered into three separate lease agreements (each, a "Lease" and collectively, the "Leases") with Hightower Phase I Owner, LLC, a Delaware limited liability company (the "Landlord"), for three industrial buildings located in Houston, Texas ("Building 1," "Building 2," and "Building 3").”

LAS VEGAS SANDS CORP entered into 5.300% Senior Notes due 2031 and 5.650% Senior Notes due 2033 Indenture with U.S. Bank Trust Company, National Association valued at $500 million of 5.300% Senior Notes due 2031 and $500 million of 5.650% Senior Notes due 2033 (effective 2026-05-13).

“On May 13, 2026, Las Vegas Sands Corp. (the “Company”) completed its previously announced underwritten public offering of an aggregate principal amount of $500 million of the Company’s 5.300% Senior Notes due 2031 (the “2031 Notes”) and $500 million of the Company’s 5.650% Senior Notes due 2033 (the “2033 Notes” and, together with the 2031 Notes, the “Notes”).”

Aquestive Therapeutics, Inc. entered into Credit Agreement with Oaktree Fund Administration, LLC, as administrative agent, and certain funds managed by Oaktree Capital Management, L.P. valued at term loan facility of up to $150.0 million (effective 2026-05-12).

“On May 12, 2026 (the “Effective Date”), Aquestive Therapeutics, Inc. (the “Company”) entered into a five-year term loan facility of up to $150.0 million (the “Term Loan”)”

Allogene Therapeutics, Inc. entered into Second Amended and Restated Shareholders’ Agreement with Overland Therapeutics Inc. and HH BioPharma Holdings Ltd. valued at Restructuring of Allogene’s equity ownership and governance rights with respect to Overland (effective 2026-05-12).

“The Shareholders Agreement amends and restates the prior shareholders’ agreement and reflects a restructuring of Allogene’s equity ownership and governance rights with respect to Overland.”

Allogene Therapeutics, Inc. terminated Exclusive License Agreement, dated December 14, 2020, as amended on May 24, 2024 with Overland Therapeutics (SH) Co. Ltd. and Overland Therapeutics Inc. valued at No termination payments were made; upfront payment $40.0 million and non-cash consideration of $79.0 (effective 2026-05-12).

“The Termination Agreement provides that the License Agreement is terminated in its entirety, subject to certain customary survival provisions.”

Honda Auto Receivables 2026-2 Owner Trust entered into Securities Account Control Agreement with Issuer, Indenture Trustee, and Securities Intermediary (U.S. Bank National Association) valued at Maintenance of certain accounts by the Securities Intermediary (effective 2026-05-13).

“A Securities Account Control Agreement (the "Securities Account Control Agreement"), by and among the Issuer, the Indenture Trustee and the Securities Intermediary, pursuant to which the Securities Intermediary will maintain certain accounts.”

Honda Auto Receivables 2026-2 Owner Trust entered into Administration Agreement with Issuer, AHFC, as sponsor and administrator, AHR LLC, as depositor, and the Indenture Trustee valued at Provision by AHFC of certain services relating to the Notes (effective 2026-05-13).

“An Administration Agreement (the "Administration Agreement"), among the Issuer, AHFC, as sponsor and administrator, AHR LLC, as depositor, and the Indenture Trustee, relating to the provision by AHFC of certain services relating to the Notes.”

Honda Auto Receivables 2026-2 Owner Trust entered into Indenture with Issuer, U.S. Bank National Association, as securities intermediary, and Indenture Trustee, and AHFC, as servicer valued at Issuance of the Notes pursuant to the Indenture (effective 2026-05-13).

“An Indenture (the "Indenture"), by and among the Issuer, U.S. Bank National Association, as securities intermediary (the "Securities Intermediary"), and the Indenture Trustee, and acknowledged and accepted by AHFC, as servicer, pursuant to which the Issuer will cause the issuance of the Notes.”

Honda Auto Receivables 2026-2 Owner Trust entered into Asset Representations Review Agreement with Honda Auto Receivables 2026-2 Owner Trust, AHFC, as sponsor and servicer, and Clayton Fixed Income Services LLC valued at Review of certain representations with respect to the Receivables (effective 2026-05-13).

“An Asset Representations Review Agreement (the "Asset Representations Review Agreement"), among the Trust, AHFC, as sponsor and servicer, and Clayton Fixed Income Services LLC, as asset representations reviewer, relating to the review of certain representations with respect to the Receivables.”

Honda Auto Receivables 2026-2 Owner Trust entered into Sale and Servicing Agreement with AHR LLC, as seller, AHFC, as servicer, RPA seller and sponsor, and U.S. Bank Trust Company, National Association, as indenture trustee valued at Transfer of receivables and related property to the Issuer (effective 2026-05-13).

“A Sale and Servicing Agreement (the "Sale and Servicing Agreement"), among AHR LLC, as seller, AHFC, as servicer, RPA seller and sponsor, and acknowledged and accepted by U.S. Bank Trust Company, National Association, as indenture trustee (the "Indenture Trustee"), pursuant to which the Receivables and related property were transferred to the Issuer.”

Honda Auto Receivables 2026-2 Owner Trust entered into Amended and Restated Trust Agreement with AHR LLC, The Bank of New York Mellon, and BNY Mellon Trust of Delaware valued at Amended and restated trust agreement pursuant to which the Issuer was formed (effective 2026-05-13).

“An Amended and Restated Trust Agreement (the "Amended and Restated Trust Agreement"), among AHR LLC, The Bank of New York Mellon, as owner trustee, and BNY Mellon Trust of Delaware, as Delaware trustee, which amended and restated the Trust Agreement, dated as of April 6, 2026, pursuant to which the Issuer was formed.”

Honda Auto Receivables 2026-2 Owner Trust entered into Receivables Purchase Agreement with American Honda Finance Corporation and American Honda Receivables LLC valued at Sale of certain asset backed notes - registration of agreements under Item 1.01 (effective 2026-05-13).

“In connection with the sale of certain of the Class A-1, Class A-2a, Class A-2b, Class A-3 and Class A-4 Asset Backed Notes (together, the "Underwritten Notes") of Honda Auto Receivables 2026-2 Owner Trust (the "Issuer"), which are described in the Final Prospectus dated May 5, 2026 and which were issued on May 13, 2026 (the "Closing Date"), the Registrant is filing the agreements listed below, each dated as of the Closing Date.”

RYVYL Inc. entered into Agreement and Plan of Merger with RTB Digital, Inc. (effective 2025-09-28).

“On September 28, 2025, RYVYL Inc. (“Ryvyl”), RYVYL Merger Sub Inc. (“Merger Sub”), a wholly owned subsidiary of Ryvyl, and RTB Digital, Inc. (“RTB”) entered into an Agreement and Plan of Merger, (the “Merger Agreement”), as subsequently amended.”

Assertio Holdings, Inc. entered into Merger Agreement with Zydus Worldwide DMCC valued at $23.50 per share (effective 2026-05-13).

“On May 13, 2026, Assertio Holdings, Inc. (the “ Company ” or “ Assertio ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Zydus Worldwide DMCC”

Nauticus Robotics, Inc. amended Second Amendment to the Term Loan Agreement with each Lender (effective 2026-05-11).

“On May 11, 2026, the Company entered into a Second Amendment to the Term Loan Agreement (the “Second Amendment”) with each Lender, pursuant to which the conversion price was reduced to $2.20 for the period ending on May 21, 2026.”

Nauticus Robotics, Inc. amended Amendment No. 2 to the Asset Purchase Agreement with SeaTrepid International, L.L.C., SeaTrepid Deepsea LLC, Remote Inspection Technologies, L.L.C. and certain individual selling persons (effective 2026-05-11).

“On May 11, 2026, the Company entered into an Amendment No. 2 to the Asset Purchase Agreement (the “Amendment No. 2”) with the Sellers, pursuant to which the Company and the Sellers amended certain payment terms of the Purchase Agreement.”

Whitehawk Therapeutics, Inc. entered into Securities Purchase Agreement with each of the purchasers named therein (the "PIPE Investors") valued at $87,500,000 (effective 2026-05-12).

“On May 12, 2026, Whitehawk Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with each of the purchasers named therein (the “PIPE Investors”), pursuant to which the Company agreed to sell to the PIPE Investors (i) 4,330,866 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $3.92 per share, and (ii) 17,991,021 pre-funded warrants to acquire Common Stock (the “Pre-Funded Warrants”), at a purchase price of $3.9199 per Pre-Funded Warrant, for an aggregate purchase price of $87,500,000 (collectively, the “PIPE Financing”).”

Aquaron Acquisition Corp. entered into Promissory Note with HUTURE Ltd. valued at $4,000 (effective 2026-05-07).

“The Company issued, on May 7, 2026, an unsecured promissory note in the total principal amount of $4,000 (the “ Promissory Note ”) to HUTURE Ltd. (“ Huture ”).”

Aquaron Acquisition Corp. amended Trust Agreement Amendment with Continental Stock Transfer & Trust Company.

“Aquaron Acquisition Corp., a Delaware corporation (the “ Company ,” “ we ,” “ us ” or “ our ”) entered into an amendment (the “ Trust Agreement Amendment ”) to the Investment Management Trust Agreement, dated October 3, 2022 (the “ Trust Agreement ”), with Continental Stock Transfer & Trust Company, as trustee (“ Trustee ”).”

Tempus AI, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $460.0 million aggregate principal amount (effective 2026-05-12).

“On May 12, 2026, Tempus AI, Inc. (the “ Company ”) completed its previously announced private offering (the “ Offering ”) of $460.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “ Notes ”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $60.0 million principal amount of the Notes. The Notes were issued pursuant to an indenture, dated May 12, 2026 (the “ Indenture ”), between the Company and U.S. Bank Trust Company, National Association, as trustee.”

GP-Act III Acquisition Corp. entered into Non-Redemption Agreements with one or more shareholders of the Company (effective 2026-05-11).

“On May 11, 2026, GP-Act III Acquisition Corp., a Cayman Islands exempted company (the “Company”), and GP-Act III Sponsor LLC, the Company’s sponsor (“Sponsor HoldCo”), entered into agreements (collectively, the “Non-Redemption Agreements”) with one or more shareholders of the Company”

Vivakor, Inc. entered into Third Amendment to Loan Agreement Fourth Forbearance Agreement and Registration Rights Agreement with J.J. Astor & Co. (effective 2026-02-27).

“On February 27, 2026, the Company and the Lender entered into a Third Amendment to Loan Agreement Fourth Forbearance Agreement and Registration Rights Agreement (the “Loan Agreement Amendment No. 3”) and $993,750 Original Principal Amount Junior Secured Promissory Note (the “Fourth Note”).”

Vivakor, Inc. entered into $993,750 Original Principal Amount Junior Secured Promissory Note (the “Fourth Note”) with J.J. Astor & Co. (effective 2026-02-27).

“On February 27, 2026, the Company and the Lender entered into a Third Amendment to Loan Agreement Fourth Forbearance Agreement and Registration Rights Agreement (the “Loan Agreement Amendment No. 3”) and $993,750 Original Principal Amount Junior Secured Promissory Note (the “Fourth Note”).”

Vivakor, Inc. entered into Fourth Forbearance, Note Payment and Registration Rights Amendment Agreement with J.J. Astor & Co. (effective 2026-02-05).

“On February 5, 2026, the Company and the Lender entered into a fourth Forbearance, Note Payment and Registration Rights Amendment Agreement (the “Fourth Forbearance Agreement”), pursuant to which (a) the parties agreed that $5,995,722.21 was then outstanding, due and payable under the Second Note and (b) the Maturity Date of the Second Note was extended to as late as January 1, 2027, and (c) the Company agreed to pay the outstanding balance of the Second Note in the following installments, with payments, payable, at the option of the Company, either in cash or under certain conditions in Conversion Shares issued at the Default Conversion Price that are immediately salable by the Lender under Rule 144, as follows: (i) $50,000 per week commencing Monday, April 6, 2026, (ii) $100,000 per week commencing Monday, July 6, 2026, (iii) $150,000 per week commencing Monday, October 5, 2026, and (iv) $250,000 per week commencing Monday, December 7, 2026, with the outstanding balance to be paid in”

Vivakor, Inc. entered into Additional Junior Secured Convertible Note (the “Third Note”) with J.J. Astor & Co. valued at $1,620,000 (effective 2025-10-09).

“On October 9, 2025, the Company and Lender entered into an Additional Junior Secured Convertible Note (the “Third Note”), under which the Company agreed to issue the Lender the Third Note in the principal amount of $1,620,000, with the Company receiving proceeds of $1,152,000 before subtracting $53,000 for legal fees and origination fees.”

Vivakor, Inc. entered into Second Forbearance and Amendment to Loan Agreement and Notes with J.J. Astor & Co. (effective 2025-10-08).

“On October 8, 2025, the Company entered into a Second Forbearance and Amendment to Loan Agreement and Notes, which amended the terms of the Loan Agreement, Initial Note, the RRA, the Second Note and the First Forbearance Agreement (the “Second Forbearance Agreement”).”